Inventiva S.A.

Inventiva S.A. filed an amendment to correct an error in a July 29, 2026 press release, stating the potential proceeds for Tranche C of its Debt Financing Transaction are €55 million, not €20 million. The company also reported preliminary financial results for the first half of 2026, with cash and cash equivalents totaling €166.1 million and €67.8 million in short-term deposits as of June 30, 2026. Inventiva expects to finance operations until Q2 2027 with current funds, extending to Q1 2028 if Tranche C and warrants are fully exercised, though current cash is not sufficient for the next 12 months.

Inventiva announced preliminary financial results for the first half of 2026, reporting cash and cash equivalents of €166.1 million and short-term deposits of €67.8 million as of June 30, 2026. Net cash used in operating activities was (€48.7) million, while R&D expenses increased to (€50.1) million. The company generated €50.9 million from financing activities, including a €103 million equity offering and €75 million debt financing, partially offset by €62 million EIB loan repayment and €50 million warrant repurchase. Inventiva expects to finance operations until the end of Q2 2027 with existing funds, but notes current cash is insufficient for the next 12 months without further financing.

Inventiva announced the completion of its EIB warrant restructuring, a key component of its broader refinancing strategy. The company issued approximately 15.7 million new warrants to the European Investment Bank (EIB) and simultaneously cancelled all remaining Legacy EIB Tranche B Warrants. This move simplifies Inventiva's capital structure by eliminating anti-dilution protection mechanisms and a put option present in the old warrants, providing increased financial flexibility.

Inventiva announced the results of its Combined Shareholders’ General Meeting held on June 30, 2026. Shareholders adopted all resolutions submitted for vote, with the exception of the 31st resolution. This rejected resolution, which the Board had negatively recommended, concerned empowering the Board to decide on share capital increases for a company savings plan. The compensation policy for corporate officers was approved without modification.

Inventiva S.A. announced the completion of key financial transactions, including the full repayment of approximately €62.2 million in existing European Investment Bank (EIB) Loans. Concurrently, the company repurchased 2,266,023 EIB Tranche A Warrants and 700,000 EIB Tranche B Warrants for €50 million. Inventiva also issued the first two tranches of new debt financing, comprising €35 million in Tranche A Convertible Bonds and €40 million in Tranche B Amortized Bonds, with an initial aggregate drawdown of €75 million from funds managed by BlackRock and Claret Capital Partners. Additionally, the Subscription Agreement was amended to adjust the minimum cash covenant testing mechanism and establish legal personality for bondholder representatives.

Inventiva S.A. has announced its Ordinary and Extraordinary General Meeting will be held on June 30, 2026. The meeting agenda includes the approval of the 2025 financial statements, which reported a net accounting loss of EUR 207,965,630.56. Key resolutions will address director and officer compensation, authorization for share buybacks up to 10% of capital, and various share capital increase mechanisms, including those without preemptive subscription rights and 'At-the-market' offerings. Additionally, a new resolution proposes issuing warrants to the European Investment Bank, and the renewal of two director mandates alongside the appointment of three new directors.

Inventiva S.A. announced it has begun mailing proxy cards and voting instructions to beneficial owners of its American Depositary Shares for its upcoming Ordinary and Extraordinary General Meeting. The meeting is scheduled for June 30, 2026, in Paris, France. Shareholders will vote on key items including the approval of 2025 financial statements, executive compensation, director appointments and renewals, and authorizations for share buybacks and capital increases.

Inventiva announced a comprehensive capital structure optimization, including new debt financing, an equity offering, and warrant repurchases. The company secured up to 130 million in committed debt financing from BlackRock and Claret Capital Partners, replacing its existing EIB loan and extending maturity to 2030. Additionally, Inventiva priced an underwritten offering of $120 million in American Depositary Shares and agreed to repurchase 60% of existing EIB warrants at a 40% discount, simplifying its capital structure. These actions extend the cash runway into early Q1 2028 and position the company for its anticipated Phase 3 readout in Q4 2026.

Inventiva S.A. reported its financial information for the first quarter of 2026, with cash and cash equivalents at €75.0 million and short-term deposits at €121.5 million as of March 31, 2026. This represents a decrease from €99.3 million in cash and €131.6 million in deposits as of December 31, 2025, primarily due to operating activities for the lanifibranor development program. The company estimates its current financial resources will fund operations until mid-Q1 2027, with potential extension to mid-Q3 2027 if Tranche 3 warrants are fully exercised. Inventiva also reiterated the expectation for topline results of its NATiV3 trial in Q4 2026.

Inventiva S.A. announced its Ordinary and Extraordinary General Meeting to be held on June 30, 2026, where shareholders will vote on the approval of the 2025 financial statements. The company reported a significant net accounting loss of EUR 207,965,630.56 for the year, which will be allocated to the 'Report à Nouveau' account. The agenda also includes approvals for executive compensation, renewal and appointment of directors, authorization for share buybacks up to 10% of capital, and various delegations for future share capital increases and debt security issuances.